Skip to main content

In Brief This Week: Source BioScience, Illumina; Verinata Health; PerkinElmer; Altona Diagnostics

NEW YORK (GenomeWeb News) – Source BioScience said this week that it has extended its next-generation sequencing services to include the Illumina MiSeq platform. The UK-based genomics services and molecular diagnostics firm said that it is the only commercial provider of the platform in the UK and added that the MiSeq will enable it to apply next-generation sequencing to molecular diagnostics.

Verinata Health said this week that it is launching a Monosomy X option, a test for Turner syndrome, as an add-on to its verifi prenatal test, which already detects trisomy 21 and 18 and Patau syndrome. Turner syndrome affects one in every 2,000 female births.

PerkinElmer has entered into a collaboration with the European Foundation for the Care of Newborn Infants to increase awareness of pre-eclampsia screening in Europe. PerkinElmer sells the PGIF assay kit for pre-eclampsia screening.

German firm Altona Diagnostics has launched ADT Biotech, its new Asia Pacific regional headquarters in Kuala Lumpur, Malaysia. The new firm will focus on development of PCR-based molecular diagnostic products.

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.